Catalyst Pharmaceuticals (CPRX) Revenue (2018 - 2026)

Catalyst Pharmaceuticals has reported Revenue for 9 years, with the latest figure at $149.4 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 5.63% year-over-year to $149.4 million; the trailing twelve-month figure through Mar 2026 stood at $597.0 million (up 11.65% YoY), and the FY2025 full-year result was $589.0 million, up 19.78% from the prior year.
• Revenue for Q1 2026 stood at $149.4 million, down from $152.6 million in the prior quarter.
• The five-year high for Revenue was $152.6 million in Q4 2025, with the low at $43.1 million in Q1 2022.
• Historically, Revenue has averaged $108.4 million across 5 years, with a median of $110.6 million in 2023.
• Annual changes were most pronounced in 2023 — Revenue jumped 98.12% — and 2026, when it climbed 5.63%.
• Catalyst Pharmaceuticals' Revenue stood at $60.8 million in 2022, then soared by 81.98% to $110.6 million in 2023, then climbed by 28.26% to $141.8 million in 2024, then increased by 7.61% to $152.6 million in 2025, then slipped by 2.11% to $149.4 million in 2026.
• The last three Revenue figures came in at $149.4 million (Q1 2026), $152.6 million (Q4 2025), and $148.4 million (Q3 2025), per Business Quant data.